PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25071018-8 2014 Collectively, regorafenib is a novel SHP-1 agonist exerts superior anti-tumor effects by enhancing SHP-1 activity that directly targets p-STAT3(Tyr705). regorafenib 14-25 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 99-104 27580057-5 2016 Herein, we evaluate whether regorafenib activates PTPase SHP-1 in the same way as sorafenib to abolish EMT-related invasion/metastasis in CRC. regorafenib 28-39 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 57-62 27580057-7 2016 Mechanistically, regorafenib-enhanced SHP-1 activity significantly impeded TGF-beta1-induced EMT/invasion via low p-STAT3Tyr705 level as proved by a SHP-1 inhibitor or siRNA-mediated SHP-1 depletion. regorafenib 17-28 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 38-43 27580057-7 2016 Mechanistically, regorafenib-enhanced SHP-1 activity significantly impeded TGF-beta1-induced EMT/invasion via low p-STAT3Tyr705 level as proved by a SHP-1 inhibitor or siRNA-mediated SHP-1 depletion. regorafenib 17-28 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 149-154 27580057-7 2016 Mechanistically, regorafenib-enhanced SHP-1 activity significantly impeded TGF-beta1-induced EMT/invasion via low p-STAT3Tyr705 level as proved by a SHP-1 inhibitor or siRNA-mediated SHP-1 depletion. regorafenib 17-28 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 149-154 27580057-8 2016 Conversely, overexpression of SHP-1 further enhanced the inhibitory effects of regorafenib on TGF-beta1-induced p-STAT3Tyr705 and EMT/invasion. regorafenib 79-90 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 30-35 27580057-9 2016 Regorafenib directly activates SHP-1 by potently relieving the autoinhibited N-SH2 domain of SHP-1 to inhibit TGF-beta1-induced p-STAT3Tyr705 and EMT/invasion. regorafenib 0-11 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 31-36 27580057-9 2016 Regorafenib directly activates SHP-1 by potently relieving the autoinhibited N-SH2 domain of SHP-1 to inhibit TGF-beta1-induced p-STAT3Tyr705 and EMT/invasion. regorafenib 0-11 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 93-98 27580057-12 2016 Collectively, activating PTPase SHP-1 by regorafenib focusing on its anti-EMT activity might be a useful pharmacotherapy for mCRC. regorafenib 41-52 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 32-37 26476076-2 2015 Our previous data demonstrated that regorafenib (Stivarga) is a pharmacological agonist of SH2 domain-containing phosphatase 1 (SHP-1) that enhances SHP-1 activity and induces apoptosis by targeting STAT3 signals in CRC. regorafenib 36-47 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 91-126 26476076-2 2015 Our previous data demonstrated that regorafenib (Stivarga) is a pharmacological agonist of SH2 domain-containing phosphatase 1 (SHP-1) that enhances SHP-1 activity and induces apoptosis by targeting STAT3 signals in CRC. regorafenib 36-47 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 128-133 26476076-2 2015 Our previous data demonstrated that regorafenib (Stivarga) is a pharmacological agonist of SH2 domain-containing phosphatase 1 (SHP-1) that enhances SHP-1 activity and induces apoptosis by targeting STAT3 signals in CRC. regorafenib 36-47 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 149-154 25071018-0 2014 SHP-1 is a target of regorafenib in colorectal cancer. regorafenib 21-32 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 0-5 25071018-3 2014 However, little is known about the mechanism regarding regorafenib affects SHP-1 tyrosine phosphatase activity and leads to apoptosis and tumor suppression in CRC. regorafenib 55-66 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 75-80 25071018-4 2014 Here, we found that regorafenib triggered apoptotic cell death and significantly enhanced SHP-1 activity, which dramatically decreased the phosphorylated form of STAT3 at Tyr705 (p-STAT3(Tyr705)). regorafenib 20-31 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 90-95 25071018-5 2014 Importantly, regorafenib augmented SHP-1 activity by direct disruption of the association between N-SH2 and catalytic PTP domain of SHP-1. regorafenib 13-24 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 35-40 25071018-5 2014 Importantly, regorafenib augmented SHP-1 activity by direct disruption of the association between N-SH2 and catalytic PTP domain of SHP-1. regorafenib 13-24 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 132-137 25071018-6 2014 Deletion of the N-SH2 domain (dN1) or point mutation (D61A) of SHP-1 blocked the effect of regorafenib-induced SHP-1 activity, growth inhibition and a decrease of p-STAT3(Tyr705) expression, suggesting that regorafenib triggers a conformational change in SHP-1 by relieving its autoinhibition. regorafenib 91-102 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 63-68 25071018-6 2014 Deletion of the N-SH2 domain (dN1) or point mutation (D61A) of SHP-1 blocked the effect of regorafenib-induced SHP-1 activity, growth inhibition and a decrease of p-STAT3(Tyr705) expression, suggesting that regorafenib triggers a conformational change in SHP-1 by relieving its autoinhibition. regorafenib 91-102 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 111-116 25071018-6 2014 Deletion of the N-SH2 domain (dN1) or point mutation (D61A) of SHP-1 blocked the effect of regorafenib-induced SHP-1 activity, growth inhibition and a decrease of p-STAT3(Tyr705) expression, suggesting that regorafenib triggers a conformational change in SHP-1 by relieving its autoinhibition. regorafenib 91-102 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 111-116 25071018-6 2014 Deletion of the N-SH2 domain (dN1) or point mutation (D61A) of SHP-1 blocked the effect of regorafenib-induced SHP-1 activity, growth inhibition and a decrease of p-STAT3(Tyr705) expression, suggesting that regorafenib triggers a conformational change in SHP-1 by relieving its autoinhibition. regorafenib 207-218 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 63-68 25071018-7 2014 In vivo assay showed that regorafenib significantly inhibited xenograft growth and decreased p-STAT3(Tyr705) expression but induced higher SHP-1 activity. regorafenib 26-37 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 139-144 25071018-8 2014 Collectively, regorafenib is a novel SHP-1 agonist exerts superior anti-tumor effects by enhancing SHP-1 activity that directly targets p-STAT3(Tyr705). regorafenib 14-25 protein tyrosine phosphatase non-receptor type 6 Homo sapiens 37-42